AC Immune Hosts Investor Webinar Highlighting the Power of its MorphomerTM Platform to Enable Precision Medicine for Neurodegenerative Disease
Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host an investor webinar today to discuss the unique benefits of the Company’s innovative MorphomerTM technology platform, which generates first-in-class therapeutic and diagnostic candidates to power AC Immune’s precision medicine approach for neurodegenerative diseases. The live webinar begins at 10am ET and can be accessed here.